

84. (Original) The immunogenic composition of claim 109, formulated in a dose of 10^3 to 10^6 PFU.

85. (Original) The immunogenic composition of claim 109, formulated for administration to the upper respiratory tract by spray, droplet or aerosol.

86. (Original) The immunogenic composition of claim 109, wherein the recombinant RSV elicits an immune response against either human RSV A or RSV B or both human RSV A and RSV B.

87-197. (Cancelled)

Rule 1.26
~~198.~~ 88. (Rejoined-Currently Amended) A method for producing an infectious attenuated recombinant RSV particle from one or more isolated polynucleotide molecules encoding said RSV, comprising:

expressing in a cell or cell-free lysate an expression vector comprising an isolated polynucleotide comprising a recombinant RSV genome or antigenome having one or more shifted RSV gene(s) or genome segment(s) within said recombinant genome or antigenome that is/are positionally shifted to a more promoter-proximal or promoter-distal position relative to a position of said RSV gene(s) or genome segment(s) within a wild type RSV genome or antigenome, and RSV N, P, L and M2ORF1 RNA polymerase elongation factor proteins.

~~199.~~ 89. (Rejoined-Currently Amended) The method of claim 198, wherein the recombinant RSV genome or antigenome and the N, P, L and M2ORF1 RNA polymerase elongation factor proteins are expressed by two or more different expression vectors.

90-207. (Cancelled)